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and 92+/-4.3%) versus the nonCSC populations (7.1% and 6.4%). (n=4 experiments/isolation procedure).
During these analyses, we unexpectedly discovered that a large number of canonical ovarian oncogenes and tumor suppressors localized to MBs in epithelial ovarian cancer cells. These included HER-2/neu, c-myc and K-ras, p53, BRCA1, BRCA2 and others. This result provided a potential molecular mechanism for the tumorigenic property of MBs and could serve as a novel therapeutic method for treating ovarian cancer in future studies. To our knowledge, this is the first report on ovarian cancer proteins on midbodies. We hope to garner additional funding to pursue this new discovery and determine how MB binding of these proteins influences ovarian tumor cell.
Task 2. Test the tumorigenic potential of MBs.
We next tested MB-positive cells that were isolated based on MB fluorescence. We used the robust MB marker, MKLP-1 to construct an MKLP-1-GFP fusion protein in both SKOV3 and OVCAR-3 cells. We used flow cytometry to isolate MB-positive cells from these populations.
To assay for tumor potential we grew cells in soft agar (anchorage-independent growth). We observed a dramatic increase in soft agar growth in MB-positive SKOV cells, colony #: 107+/-I 6, versus MB-negative SKOV cells, 25 .2+/-0.2, p<0.001 and a lower but significant increase in MB-positive OVCA cells (OVCAR-3), colony #: 79+/-3.1 vs. 11+/-1.1. We did not address why there were differences in the degree of soft agar growth between these cells lines, but rather, we focused on the trend, namely that MB-positive cells vs. MB-negative cells have greater tumor-like potential.
We used an independent method to test for the ability of MBs to enhance tumor potential. In this assay, we prevented receptor-mediated degradation of MBs (figure right) by depleting the MB-autophagy-receptor, NBR1. shRNA depletion of NBR1 as in our previous studies (Kuo et al, 2011) blocked autophagic degradation of MBs and increased the percent of MB+ cells by a level similar to those in Kuo et al., 2011 and this was accompanied by an increase in soft agar growth by percentages similar to those observed for cells isolated by MKLP-GPF, above (4.13-fold greater than controls). During the course of this work, we discovered another autophagy protein, NipSnip2. It had an enhanced effect on MB degradation when depleted compared to NBR1 (8.19 -fold increase in colony number over control (scrambled shRNA).
Task 3. Test if specific targeting of MBs for autophagic degradation is a therapeutic strategy for ovarian cancer.
We showed that expression of NBR1-GFP or NipSnip2-GFP increased autophagy-mediated degradation of MBs over GFP control cells (~ 4-fold fewer MBs than GFP control, Fig. 3 ) in two different ovarian cancer cells (SKOV3, OVCAR-3) presumably through more efficient binding of these proteins to MBs facilitating their uptake into the MB-selective autophagy pathway. GFP and the GFP-tagged proteins were all expressed at the same levels then analyzed for soft agar colony number. Soft agar colony number was decreased in GFP-NBR1 expressing cells vs. GFP alone expressing cells with fold differences very similar to that observed in other cancers in our studies 74+/-2.1 vs. 11+/-0.7; Kuo et al., 2011) . This result has important implications for ovarian tumor therapy.
From all of these studies we conclude that MBs influence the tumorigenic-like properties in ovarian cancer cells. More specifically, increasing MBs in ovarian cancer cells increases tumor-like activity whereas decreasing MBs decreases tumor-like properties of cells. Future studies will be designed to test if the MB-bound oncogenes and tumor suppressors (above) play a role in this process. We completed nearly all the proposed work on in vitro cell biology studies. This work took more time than anticipated, so we were unable to make progress on the mouse orthotopic tumor experiments. We hope to address this task in the near future. *MB-positive ovarian cancer cells contain stem cell antigens.
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INTRODUCTION
Cell division culminates in the separation of two genetically identical daughter cells 1 . During division, cell fate determinants segregate asymmetrically to stem cell progeny 2 . The two spindle poles organized by differentially-aged centrosomes contribute to this asymmetry 2, 3 in that the older centrosome is inherited by the daughter cell that retains the stem cell fate [4] [5] [6] .
Abscission completes cell division by severing the intercellular bridge between the two future daughter cells 1, 7 . Within the intercellular bridge lies the midbody (MB), a large proteinaceous organelle 7-10 that was previously thought to detach from cells and disintegrate extracellularly as a remnant 7, 8 . Recent studies show that post-abscission MBs or MB derivatives (MB d s) can be retained by daughter cells, suggesting alternative fates for these organelles 9, 11, 12 .
The fate and function of MB d s is unclear. In neural progenitors, MB d s possess the putative stem cell marker CD133/prominin-1 and are proposed to participate in intercellular signaling during neural development 13, 14 . MB d s can be degraded by autophagy (see below) 12 , but the relationship between MB d loss or retention and the physiological state of cells is unknown.
During autophagy (macroautophagy), double membrane-bound autophagosomes assemble, engulf cytoplasmic material, and fuse with lysosomes for degradation [15] [16] [17] [18] . Autophagy is required for cellular homeostasis, eliminating defective ubiquitin-tagged proteins and organelles [16] [17] [18] [19] , clearing cell fate determinants and cell remodeling [20] [21] [22] . Defects in autophagy contribute to many disorders, including neurodegeneration 23 , hepatomegaly 24 and aging 15, 18 .
Here we show that MB d s accumulate in stem cells and are lost upon differentiation. They are selectively degraded by linking the NBR1 autophagic receptor to the Cep55 MB protein. MB d s accumulate by evasion of autophagosome encapsulation, asymmetric inheritance, and maintenance of low autophagic activity. Reprogramming efficiency and in vitro tumorigenicity are increased following experimental elevation of MB d levels suggesting non-mitotic roles for these organelles in stem and cancer cells.
RESULTS
Post-mitotic midbodies accumulate within cells
Multiple MB d s were observed in subpopulations of cells by immunofluorescence (IF), but their precise location was unclear (up to 20; Fig. 1a, b ). Three-dimensional reconstruction of immunofluorescent images revealed multiple MB d s inside polarized and nonpolarized cells ( Fig. 1c, d ). Immuno-electron microscopy confirmed this localization and revealed ultrastructural features characteristic of MB d s 8, 14 (Fig. 1e ). About 70% of cell-associated MB d s were trypsin-resistant, suggesting that they were intracellular ( Fig. 1f ). This intracellular localization of MB d s suggested that they might accumulate in cells through successive divisions (below).
MB d s were also released from cells. In 2-day co-cultures of HeLa cells stably expressing either monomeric RFP (cytoplasmic marker) or MKLP1-GFP (MB marker), about 7% of MKLP1-GFP+ MB d s associated with RFP+ cells (Fig. 1g ). Such free MB d s were also generated by other cell types (e.g. human adult fibroblasts, HeLa; 1-10%). These observations resolve the conflict of previous studies suggesting that MB d s are either retained and degraded 9, 11, 12 or released as remnants after abscission 8 . We show that MB d s accumulate in some cells ( Fig. 1a-d ) but not others, and it is this cell type-specific difference in MB d -accumulation that is the focus of this study.
MB d s are inherited by the cell with the older centrosome
Multiple MB d s often clustered around the centrosome or spindle pole (ref. 9 and data not shown), reminiscent of MB d -sized aggresomes, which segregate to one daughter cell under control of centrosomes 25, 26 . Moreover, centrosome age-dependent differences in signaling were observed late in cytokinesis 27 . These centrosome age-related differences led us to examine the relationship between centrosomes and MB d inheritance.
In G1, the centrosome contains one mother centriole (MC) and one daughter centriole (DC) 3 . After centriole duplication, three generations of centrioles are present: an older mother, a younger mother and two new daughters 3, 27 . The centrosome with the older MC is termed the older centrosome 4, 5 . GFP-tagged centrin1 (CETN1-GFP) 28 expressed in mitotic HeLa cells was brightest at one of the four centrioles (92.2% of cells, n=116; Fig. 2a ) and turned over very slowly (FRAP t 1/2 ~4 hours and ref. 5). The brightest centriole remained so from metaphase to late cytokinesis (91.3% of cells, n=46; supplementary information, Fig.  S1a ), suggesting that it was the older MC. This was confirmed by staining with the older centrosome marker, hCenexin1 27 (~90% of HeLa and MCF-7 cells, n=143 and n=347, respectively; Fig. 2b ). Several other centriole antigens also showed intrinsic age-related differences in labeling (supplementary information, Fig. S1b ).
Using CETN1-GFP to identify the older MC; bright-field imaging to follow MB dynamics in living cells; and immunofluorescence to confirm MB d inheritance, we determined that MB d s were preferentially inherited by the cell with the older centrosome. This was observed in pluripotent human embryonic stem cells (hESCs; 83.3% of H9, n=18; Fig. 2d ), immortalized somatic cells (91.3% of hRPE-1, n=23) and cancer cells (U2OS: 84.6%, n=13; HeLa: 75.0%, n=24; Fig. 2c ). We conclude that most inherited MB d s are asymmetrically transferred to the daughter cell with the older centrosome in several cell types.
MB d s accumulate in stem cells in vivo
Other studies have shown that the older centrosome is asymmetrically inherited by the stem cell during asymmetric divisions in the Drosophila male germline 4 and the mouse neocortex 5 . The association of the older centrosome with both MB d s and stem cell divisions led us to ask whether MB d s were found in stem cell niches. To address this, we determined the localization of MB d s in human and mouse tissues. In seminiferous tubules of testes, MB d s were confined to the basal compartment, the site of germline stem cells and their mitotic progeny (both capable of self-renewal 29,30 ) ( Fig. 3a , up to 8 puncta/cell, 5-μm section). Electron microscopy also revealed multiple cytoplasmic structures with features characteristic of MB d s within these cells (Fig. 3b, c ).
In the ventricular zone (VZ, Sox2+ 31 ) of embryonic mouse brains, CD133-labeled MB d s were associated with neural progenitors 13, 14 ( Fig. 3d and Supplementary information, Fig.  S2 ). During asymmetric divisions, intracellular MB d s were usually found in ventricle-facing daughter cells (progenitors; 75%, n=8) and not in daughters with presumed committed fates 5 . MB d s in the human hair follicle were also confined to a subpopulation of cells in the stem cell niche, the bulge 32 , suggesting distinct properties of this subpopulation ( Fig. 3e , f). MB d s were also enriched in β1-integrin+ 33 mouse skeletal muscle progenitors (SMPs; 4fold) over non-SMP cells. These observations suggested that MB d s were selectively retained and accumulated during successive stem cell divisions in vivo.
MB d s accumulate in stem cells in vitro
To rigorously test the idea that MB d s are selectively inherited by stem cells, we examined MB d fate during stem cell differentiation and somatic cell reprogramming. MB d 'accumulation' was assessed by counting cells with >1 MB d , as all cells can transiently acquire one MB d after abscission (below). MB d -accumulation decreased ~8-fold upon differentiation of hESCs (H1-OGN) to fibroblast-like cells (dH1f; Fig. 3g , h). Differentiation was judged by loss of embryonic stem cell markers (Oct4, Sox2, Klf4, Nanog) and gain of the CD13 differentiation marker 34, 35 . In contrast, MB d -accumulation increased ~7-fold after reprogramming dH1f cells to iPSCs 34, 36 (dH1f-iPS; Fig. 3h , i). We conclude that MB d -accumulation in vitro reflects that observed in vivo, and can be manipulated by altering the potency status of cells.
MB d -accumulation is enhanced in tumor-derived cells
We next examined differences in MB d -accumulation among cell lines derived from stem cells, normal dividing cells and cancer cells ( Fig. 4a ). MB d -accumulation was low in primary and telomerase-immortalized normal cells and significantly higher in hESCs and iPSCs (~7-fold on average; Fig. 4a ). Most cancer cells exhibited even higher levels of MB daccumulation. For example, MB d -accumulation in tumorigenic MCF-10AT and MCF-10CA1a cells was much higher than in the normal MCF-10A parental line. The common ability of stem cells and cancer cells to accumulate MB d s, express stem cell markers 37 and possess stem cell properties 38, 39 suggests a relationship between MB daccumulation, tumorigenicity and cancer 'initiating' or 'stem' cells defined by the CSC theory 40 .
MB d -accumulation does not correlate with cell proliferation rate
A simple explanation for cell type-specific differences in MB d -accumulation is variability in proliferation rates. Slower division rates could allow more time for MB d degradation, as recently proposed 12 . However, we observed no correlation between population doubling-time and MB d -accumulation ( Fig. 4a) . It was still possible that MB d -accumulating cells cycled faster than the bulk population. However, a cohort of cells pulse-labeled with EdU 41 showed a proportional decrease in EdU intensity, reflecting dilution of dye after successive divisions ( Fig. 4b ) and indicating that MB d -accumulating and non-accumulating subpopulations had similar cycling rates ( Fig. 4c, d ).
MB d -accumulating cells evade membrane encapsulation of MB d s
We next asked if MB d s occupied different sites within MB d -rich and MB d -poor cells. To test this, we used the Fluorescence Protease Protection (FPP) assay 42 to monitor degradation of MB d s following plasma membrane permeabilization and protease addition ( Fig. 5a ). Under these conditions, MKLP1-GFP+ MB d s were degraded in MB d -rich HeLa cells but not in MB d -poor hRPE-1 cells indicating that MB d -poor cells sequestered MB d s in membranebound compartments whereas MB d -rich cells accumulated them in the cytoplasm (Fig. 5b) . Importantly, the integrity of intracellular organelles was maintained during the course of these experiments (supplementary information, Fig. S3 ).
Stem cells and cancer cells evade lysosomal degradation of MB d s
The protease resistance of MB d s and low MB d -accumulation in MB d -poor hRPE-1 cells ( Fig. 4a and 5b) suggested that MB d s were delivered to a membrane-bound compartment for degradation, such as the lysosome. Indeed, MB d s were often found within LAMP2 43 -labeled lysosomes in MB d -poor cells (Fig. 5c ). To test this further, we examined the fate of newlyformed MB d s in synchronous populations of MB d -poor cells (Fig. 5d ). Three hours after release from mitosis, the percent of MB d + cells (MB d levels) peaked at ~40% (50% being the maximum since half the cells were 'born' without a MB d ). This was followed by a peak in MB d localization to lysosomes (~42% at 7 hours; Fig. 5d ) and then a decrease of MB d s to baseline levels (16-19 hours; Fig. 5d ). These data and the FPP data suggested that MB d s in hRPE-1 cells entered the cytoplasm, moved into lysosomes and were degraded before the next cell cycle ( Fig. 5b, d ).
If lysosomes are involved in MB d degradation, lysosomal inhibition should increase MB d levels. Indeed, when lysosomal activity was inhibited in MB d -poor hRPE-1 cells with either chloroquine or E64d/PepA protease inhibitors 44 MB d levels ( Fig. 5e ) and the percent of MB d s found within lysosomes (Fig. 5c ) were elevated. In contrast, MB d levels and the percent of MB d s in lysosomes in MB d -rich cells (hESC, MCF-7; Fig. 5c , e) were largely unaffected by lysosomal inhibition (see supplementary information, Fig. S4a ). The modest increase in MB d + HeLa cells (Fig. 5e ) was consistent with their modest MB d -accumulating ability (Fig. 4a ). We conclude that lysosomal degradation prevents MB d -accumulation in MB d -poor cells, but does not play a major role in MB d -rich cells (e.g. stem cells, CSCs) thus allowing MB d s to accumulate.
Autophagic degradation controls intracellular MB d levels
To determine how MB d s were directed to lysosomes, we explored pathways leading to lysosomal degradation. Reported autophagy levels in MCF-7 and DLD-1 cells 45, 46 suggested a relationship between autophagy and MB d fate. Low autophagy levels in MCF-7 cells resulting from a deficiency in the autophagy gene, BECN1 (also known as Atg6) 45 , are consistent with high MB d -accumulation (~26-fold over normal cells; Fig. 4a ). High autophagy levels in DLD-1 cells 46 are consistent with low MB d -accumulation (only ~1.8fold over normal cells; Fig. 4a ). In agreement with this trend was the presence of MB d s in autophagosomes of MB d -poor cells (Fig. 6a ).
Experimental reduction of autophagy activity using MEFs from Atg5-deleted mice 19 or by siRNA-mediated depletion of Atg7, increased MB d levels (Fig. 6b ). Induction of autophagy by rapamycin and lithilum chloride treatment 47, 48 in HeLa cells or by exogenous BECN1 expression in MCF-7 cells, decreased MB d levels (Fig. 6c) . These results demonstrated the role of autophagy in regulating MB d levels in different cell types, and suggested an inverse relationship between autophagic activity and MB d -accumulation. This inverse relationship was revealed in 12 cell lines by LC3-II 44, 49 or p62 44,50,51 -based measurements of autophagic activity (Fig. 6d , e and supplementary information Fig. S4b ). We conclude that MB d levels are, in part, modulated by cell type/lineage-specific autophagy ( Fig. 3g-i, 4a, 6d and 6e).
NBR1 is an autophagic receptor for MB d -specific degradation
To test whether MB d degradation involves non-specific or receptor-mediated autophagy pathways 15 , we investigated the mammalian autophagic receptors, p62 50-52 and NBR1 53, 54 . p62 is implicated in MB d clearance 12 , whereas NBR1 is untested. NBR1 and p62 localized to mitotic MBs and MB d s (Fig. 7a , top, data not shown, and ref. 12 ), suggesting that MB d degradation involves receptor-mediated autophagy. NBR1-silencing in HeLa cells increased MB d levels to Atg7-silencing levels ( Fig. 6b and 7b ), suggesting that NBR1 is likely a major autophagic receptor for MB d degradation. In contrast, p62-deletion 51 or siRNA-mediated p62 depletion had no detectable effect on MB d levels (Fig. 7b , c) or NBR1 recruitment to MB d s (Fig. 7a, bottom) .
To date, no MB d target(s) for autophagic degradation have been identified. Candidate-based screening revealed that endogenous NBR1 co-immunoprecipitated with the MB protein Cep55 in hRPE-1 cells (Fig. 7d ). Cep55 over-expression increased MB d levels ( Fig. 7e ) and the level of NBR1-negative MB d s (Fig. 7f ), presumably through NBR1 sequestration in the cytoplasm (Fig. 7g ). This suggested a role of Cep55 in NBR1-mediated MB d degradation.
We propose that the Cep55/NBR1 interaction couples MB d s to the autophagic machinery to control MB d fate.
Cells enriched in MB d s exhibit increased reprogramming efficiency
We next examined the functional consequences of manipulating MB d levels. We first tested the role of MB d s during reprogramming 34, 35, 55 in cells stably expressing NBR1-specific shRNAs (shNBR1) to increase MB d levels over controls (shNT). MB d levels increased ~1.8fold in dH1f cells, ~1.5-fold in IMR90 55 embryonic fibroblasts, and ~1.9-fold in hFib2 34 adult fibroblasts. Under these conditions, iPSC colony formation increased significantly in all three cell types depleted of NBR1: dH1f cells (up to 8.7-fold, avg. 3.1±0.5-fold), IMR90 cells (up to 4.2-fold, avg. 3.4±0.8-fold; Fig. 8a, b and supplementary information Table. S1) and adult hFib2 cells (up to 2.5-fold, avg. 1.7±0.5-fold). Similar results were obtained with different batches of viruses, different combinations of reprogramming factors, and different viral delivery systems (see Methods). Importantly, increased reprogramming following NBR1-depletion occurred without significant changes in global autophagic activity (dH1f; Fig. 8c ) or cell proliferation rate (shNBR1: 27.3±2.5hrs; shNT: 26.8±4.5hrs; n=6), suggesting that NBR1 is selective for MB d degradation.
Cancer cells enriched in MB d s exhibit increased in vitro tumorigenicity
Because MB d s selectively accumulate in stem cell niches, hESCs, and iPSCs, we reasoned that they may also accumulate in CSCs. On the basis of Hoechst 33343 extrusion, the side population (SP) of MCF-7 cells 56 was isolated. These putative CSCs showed a 7-fold increase in MB d + cells over the non-SP population (MP; Fig. 8d ).
To directly address the role of MB d s in cancer cells, MKLP1-GFP-expressing HeLa populations with high or low percentages of MB d + cells were isolated by FACS, and tested for anchorage-independent growth. Increased colony formation was observed in the "MB d high" versus the "MB d low" population, and colony formation increased with increasing MB d levels (up to 4-fold; Fig. 8e ). An increase in colony formation was also observed in MB d -enriched HeLa cells (Fig. 8f , left) and mouse hepatocarcinoma cells (134-4; Fig. 8f , right) following NBR1-silencing. Results of all three strategies suggest that MB d s in cancer cell subpopulations may contribute to their tumorigenic potential.
DISCUSSION
We have identified new roles for MB d s outside their canonical function in cytokinesis. This work provides the first evidence for MB d -accumulation in stem cells, hESCs and iPSCs in vivo and in vitro, and for dramatic MB d reduction in differentiating progeny of stem cells.
MB d s appear to function in maintaining or enhancing the pluripotency of stem cells and the tumorigenicity of cancer cells.
Our findings suggest that MB d loss that accompanies stem cell differentiation is mediated by autophagic degradation, resulting in selective elimination of MB d s in differentiated cells but retention in germ or stem cells. This process is intriguingly similar to clearance of P granule components in committed somatic cells of C. elegans, which is also mediated by autophagy 57 . Moreover, P granules contain molecules required for cell fate specification 58 , and MB d s contain stem cell markers 13, 14 and enhance cell fate conversion (present study). It is thus tempting to propose that MB d s may serve as scaffolds for organizing cell fate determinants. Equally intriguing is the observation that essentially all cancer cells examined contain MB d -accumulating subpopulations, making this a common intrinsic property of both stem cells and cancer cells. The observation that MB d -enriched cancer subpopulations exhibit enhanced in vitro tumorigenicity is consistent with the CSC model for potentiation of tumorigenicity [37] [38] [39] [40] .
Our data identify two primary mechanisms for MB d -accumulation. The first is asymmetric MB d inheritance by the daughter cell with the older centrosome (Fig. 8g, top) . In fly testes and mouse neocortex, the old centrosome segregates to the stem cell during asymmetric divisions and is accompanied by increased microtubule-anchoring ability 4-6 . MB d inheritance could be facilitated through increased anchoring of microtubules to the older centrosome, and increased microtubule binding to the MB d in the daughter cell with the older centrosome. This would be consistent with the observed MB d -accumulation in stem cells but not in their differentiated progeny. Despite the slower division rate of stem cells in vivo 59 , MB d -accumulation could still occur via this mechanism. However, our results also indicate that such asymmetry occurs in different cell types, suggesting that it may only be physiologically relevant in stem cells and CSCs.
Evasion of autophagic degradation is a second mechanism for MB d -accumulation (Fig. 8g,  bottom) . This is exemplified by the inverse relationship between MB d levels and autophagic activity, and by changes in MB d levels with manipulation of autophagy levels. MB daccumulation can also be mediated by uncoupling receptor-mediated entry into the autophagy pathway, since depletion of the NBR1 autophagic receptor or over-expression of the corresponding ligand, Cep55, increases MB d levels. In contrast, another known autophagic receptor, p62, does not appear to be involved in MB d clearance (Fig. 7b, c) . NBR1 and p62 can form a complex 53, 60 ; however, evidence suggests that they may act independently as autophagic receptors 53 . Thus, p62/NBR1 complex formation may not be a prerequisite for autophagic degradation. Since NBR1-silencing increases MB d s to levels seen following inhibition of autophagy in HeLa cells ( Fig. 6b and 7b ), NBR1-mediated autophagic degradation likely represents a major pathway for selective MB d elimination. However, it is still possible that other autophagic receptors and MB d ligands may exist and contribute to MB d degradation, even though Cep55 is the sole MB ligand for the NBR1 receptor identified thus far (Fig. 7d ). In our model, Cep55 and NBR1 and perhaps other MB d ligands and autophagy receptors, act as switches that control MB d fate. Ongoing proteomic analyses may identify other molecules and pathways for MB d degradation.
MB d levels can be further increased in autophagy-compromised Atg5 -/-MEFs when lysosome enzymes are inhibited (data not shown), suggesting that other degradative pathways may contribute to MB d degradation. Chaperone-mediated autophagy (CMA) 15, 61 , which targets ~30% of cytosolic proteins and is upregulated upon compromised autophagy 62 , is a potential candidate since multiple MB proteins contain CMA-targeting motifs (KFERQ-like motifs) 61 . The proteasome system is another major cellular degradation pathway 63 but it doesn't appear to play a role in MB d degradation (supplementary information, Fig. S5 ).
Other non-degradative processes may also regulate MB d levels. Even though elevated proliferation rate has been proposed as a factor hindering autophagic MB d degradation and causing MB d -accumulation in cancer and normal cells 12 , we didn't observe such a correlation (Fig. 4a ). Additional work is required to determine if MB d -accumulation also requires selective sequestration of previously inherited (pre-existing) MB d s, as suggested by selective accumulation of MB d s in stem cells of the testes and lateral ventricle of the brain (Fig. 3a-d) . Release of MB d s has also been observed in chicken and mouse neural progenitors 13, 14 and in human cells (ref. 8 and Fig. 1g ), and may be another, possibly minor pathway for eliminating MB d s (or for intercellular signaling 14 ). Finally, ongoing work is addressing whether MB d s are distributed to both daughters of stem cells during symmetric divisions as might be expected if MB d s are essential for stem cell function.
In summary, our results demonstrate that MB d s are more than the remnants of cytokinesis. Their fate is differentially controlled in different cell types and mediated by diverse pathways. The shared ability to accumulate MB d s by stem cells and putative CSCs, and the striking impact on cellular phenotypes following manipulation of MB d levels suggest that MB d s perform important cell type-specific functions that remain to be discovered.
METHODS
Cell lines
hESC and iPSC lines include H1 (WA01), H9 (WA09), H1-OGN (Oct4-EGFP knock-in H1) 36 , and dH1f-iPS 34 
Immunofluorescence and Immunohistochemistry
Immunofluorescence was performed as described 9, 13, 64 . To label lysosomes and autophagosomes, cells were permeabilized with 0.05% saponin in blocking buffer (10% goat serum/PBS). Preparations for immunohistochemistry were fixed with 4% paraformaldehyde/ 0.5% glutaraldehyde via perfusion. Testes were processed and stained following 2-4hr postfixation with 4% paraformaldehyde. MB-derived rings between spermatocyte syncytia 65 were observed if stained longer. Images were taken on a Zeiss Axioskop 2 microscope, a Zeiss Axiovert 200 microscope with PerkinElmer UltraView LAS spinning disc, or an Olympus BX-51 microscope. Images were processed and analyzed with MetaMorph (Molecular Devices) and Imaris (Bitplane Inc.).
Electron Microscopy
Conventional EM-Mouse tissue, fixed with 5% glutaraldehyde in 50 mM sodium cacodylate buffer (pH=7.4) for 30 min via perfusion, was diced into 1-mm cubes for 1-hr post-fixation at 4°C. Cubes were washed with cacodylate buffer, stained and embedded in Spi-pon/Araldite, and sectioned at 70-500 nm before staining with 25% uranyl acetate and Reynold's lead citrate. Images were taken on a Philips CM12 electron microscope with an Erlangshen CCD Camera (Gatan).
Immunogold EM-MCF-7 cells on coverslips were prepermeabilized for 60 sec with preperm buffer (80 mM PIPES, pH6.8, 0.5 mM EGTA, 1 mM MgCl, 0.5% Triton X-100), fixed with 4% paraformaldehyde for 10 min, labeled for MKLP1 for 1 hour, processed as described 66 using 12-nm gold-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch) and embedded in Spi-pon/Araldite. 80-nm sections were cut, stained and viewed as above.
Time-lapse imaging
CETN1-GFP-expressing lines were grown on 35-mm MatTek dishes (MatTek Corp.) or coverslips before imaging 9 . H9 hESCs were seeded on matrigel-coated dishes overnight, then transduced with CETN1-GFP, and grown for >72 hours in complete mTeSR1 medium (Stemcell Technologies). The transduced cells were imaged every 15 min in phenol red-free D-MEM/F12 medium (Invitrogen) with mTeSR1 supplement and 10 mM HEPES, and stained to confirm MB d inheritance. Duplicate dishes of transduced cells were stained for stem cell markers to ensure cell quality.
MB d quantification
Quantification was based on the markers that: 1) labeled both mitotic MBs and MB d s (MKLP1, mgcRACGAP, or Cep55); 2) labeled MBs differently than MB d s (α-tubulin or Aurora B); 3) defined cell boundaries (α-tubulin or ZO-1). Because Cep55, MKLP1, and mgcRACGAP also label centrioles and spindle midzones, cells were co-stained with centrosome antibody (e.g. 5051), and a size threshold for MB/MB d s (1 μm) was introduced to exclude non-MB d structures. Structures with MB-specific or non-MB/MB d labeling were excluded from MB d counts. Cell counts: For hESCs, 5-11 colonies were imaged from triplicates in each experiment. For other cell types, random fields were imaged until n > 500 cells. Each dividing cell was considered one cell.
Doubling time calculations
Cells were seeded (1-1.5×10 5 /60-mm dish), and total cell counts were taken by hemocytometer every 24 hours for 4 days. Alternatively, cells were seeded (2.5-5.0×10 3 / well, 96-well plates), and the absorbance from an MTS-based colorimetric assay (#G3582; Promega Corp.) was used to estimate cell counts every 24 hours. Timepoints vs. Log 10 (avg. cell counts or absorbance at that timepoint) was plotted and the slope ascertained. T 1/2 = Log 10 (2)/ slope. For some cell lines, both methods were used and gave similar results.
MB d localization assays
Extracellular trypsin treatment-MKLP1-GFP-expressing HeLa cells grown in
MatTek dishes were imaged every 3 min, and underwent no morphological changes upon replacement of media with PBS. After trypsin addition, GFP+ MB d s were monitored for 60-90 min for intensity reduction (degradation) or detachment from cells (dissociation).
Co-culture assay-Equal numbers of monomeric RFP-or MKLP-GFP-expressing cells were seeded and co-cultured in 60-mm dishes with coverslips. Cells were stained 2 days later, and the percentage of GFP+ MB d s associated with RFP+ cells was determined.
FPP assay-The FPP assay was carried out as reported 42 except cells were plated in MatTek dishes 24 hours before co-transfection of MKLP1-GFP and GAPDH-dsRed (Lipofectamine 2000, Invitrogen). Cells were permeabilized and then digested with proteinase K (50 μg ml -1 ). Constructs labeling mitochondria, peroxisomes, ER and Golgi were used as controls.
Lysosome and proteasome assays
Cells at 70% confluency were incubated with chloroquine (200 μM/PBS; Sigma), E64d + pepstatin A (E64d/PepA) (10 μg ml -1 /DMSO each; Sigma) 44, 51 or solvents alone (controls) for 22 hours before fixation. Lysosome inhibition was confirmed and visualized after 12hour DQ-Red BSA (10 μl ml -1 ; Invitrogen) incubation. Mitotic hRPE-1 cells were treated with proteasome inhibitors, MG132 (1 μM; Sigma) or lactacystin (50 μM; Sigma) 1 hour after replating.
Autophagy manipulation assays
MB d s were quantified in >500 cells in triplicate unless otherwise noted.
Protein depletion-siRNAs targeting human Atg7 67 , p62 12 , NBR1 53 (2503-2521 bp, GenBank NM 005899), Lamin A/C 9 , and GFP (5'-NNCAUGAAGCAGCACGACUUC-3') were Dharmacon. MB d levels were analyzed 48 hours after 1-nmol siRNA transfection (Oligofectamine, Invitrogen). For NBR1 and p62 experiments, only cells negative for p62 and/or NBR1 immunofluorescence were analyzed. CEP55-EGFP overexpression-MB d levels and its NBR1-association were assessed in hRPE-1 cells (1×10 5 /well, 6-well plates) 48 hours after CEP55-EGFP (1 μg), EGFP (1 μg) or mock transfection.
Beclin1 (BECN1) overexpression-MB
Biochemical assays
Protease and phosphatase inhibitors, cell lysates, SDS-PAGE and immunoblotting were purchased or carried out as described 9 unless specified.
Autophagy flux determination-Lysates of E64d/PepA (I) and DMSO (U) treated cells were blotted for α-tubulin and LC3. LC3-II levels were determined and normalized to αtubulin using ImageJ. Autophagic flux = |100 -((U/ I LC3-II level) × 100)|.
Immunoprecipitation-hRPE-1 cell lysates (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM EGTA, 1% Triton X-100, 10% glycerol, 4°C) were pre-cleared for 1 hour with protein G-plus conjugated agarose beads (Santa Cruz) at 4°C, incubated with 2 μg normal IgG, anti-Cep55 or anti-NBR1 antibodies for 3 hours at 4°C, and incubated overnight at 4°C with 25 μl protein G-plus beads. Following washes with lysis buffer and elution, immunoprecipitated proteins were analyzed by SDS-PAGE and immunoblotting.
Assays for MB d function
Cellular reprogramming-Viral production, transduction and reprogramming were performed as described 34, 35, 55, 68 . Commercially-available shRNA against NBR1 (pSM2c-shNBR1, V2MM_36901; 4-22 bp, GenBank NM 005899) was cloned into pGIPZ lentiviral vector (Open Biosystems). Embryonic fibroblasts (IMR90), adult fibroblasts (hFib2) and dH1f cells were transduced with either NBR1-specfic or non-targeting shRNA vector, and puromycin-selected to establish NBR1-depleted (shNBR1) and control (shNT) lines. dH1f (2.5×10 4 /assay) were reprogrammed with lentiviral vectors 69 (Addgene #21162 and 21164) expressing OCT4, SOX2, KLF4 and c-MYC 34, 35, 68 whereas the reprogramming of IMR90 and hFib2 cells (5×10 4 /assay) also included lentiviral vectors expressing Nanog and Lin28 55, 69 (Addgene #21163) . iPSC colonies were quantified on day 21 based on Tra-1-60 expression using ImageJ, as reported 35, 68 , and with parameters: ≥148 (threshold), 0.5-1 (circularity), and either 10-infinity or 30-infinity (size).
Side Population (SP) assay-
The assays were carried out as previously described 56 in MCF-7 cells. The MB d levels in SP and non-SP populations were determined as described above.
Soft-agar assays-"MB d high" and "MB d low" subpopulations of MKLP1-GFPexpressing HeLa cells were separated by FACS, and plated in soft-agar (2.5 ×10 4 /well, 6well plates). The MB d levels were determined 12-15 hours after plating aliquots of subpopulations onto coverslips. For the NBR1-silencing soft-agar assay, NBR1-depleted (shNBR1) and control (shNT) cells (1×10 5 /100-mm dish) were plated. For both assays, cells were grown for ~3 weeks at 37°C, and stained as described 70 . Colonies were quantified microscopically, and the average from triplicate wells or plates presented.
Antibodies
Antibodies to the following proteins/tags were used in this study-Atg5 , d) After a 96-hr chase period, EdU levels were compared between cells with MB d numbers of >1, 1, and 0 (y-axis) in HeLa (c) and SAOS-2 cells (d). In both cases, no significant differences were noted (c, p=0.2101; d, p=0.5609, one-way ANOVA, with at least 800 cells analyzed for each experiment, n=3), indicating similar cycling rates among different subpopulations of cells. (b-d) Each graph is a representative experiment. Cells analyzed shown by green points, median depicted by vertical red lines, and horizontal red lines with ticks illustrate the interquartile range. 
